Title: Identification of Inadequate Responders to Advanced Therapy Among Commercially-
Insured Adult Patients with Crohn’s Disease and Ulcerative Colitis in the United States
Version: 3 Date: 06 Feb 2023
Reviewer's report:
The authors devised an algorithm for inadequate response to 1-year advanced therapy in IBD
patients and identified several characteristics independently associated with inadequate response
both in CD and UC patients from one of claims data in US.
Although careful interpretations of data are needed because of its being retrospective analysis,
the authors reasonably included only those who newly started advanced therapy and the results
are generally consistent with what we already know about inadequate response to advanced
therapy from the cohort studies or clinical trials in IBD.
Title: Identification of Inadequate Responders to Advanced Therapy Among Commercially-
Insured Adult Patients with Crohn’s Disease and Ulcerative Colitis in the United States
Version: 3 Date: 06 Feb 2023
Reviewer's report:
The authors devised an algorithm for inadequate response to 1-year advanced therapy in IBD
patients and identified several characteristics independently associated with inadequate response
both in CD and UC patients from one of claims data in US.
Although careful interpretations of data are needed because of its being retrospective analysis,
the authors reasonably included only those who newly started advanced therapy and the results
are generally consistent with what we already know about inadequate response to advanced
therapy from the cohort studies or clinical trials in IBD.
Please review this paper.
user
Title: Identification of Inadequate Responders to Advanced Therapy Among Commercially-
Insured Adult Patients with Crohn’s Disease and Ulcerative Colitis in the United States
Version: 3 Date: 06 Feb 2023
Reviewer's report:
The authors devised an algorithm for inadequate response to 1-year advanced therapy in IBD
patients and identified several characteristics independently associated with inadequate response
both in CD and UC patients from one of claims data in US.
Although careful interpretations of data are needed because of its being retrospective analysis,
the authors reasonably included only those who newly started advanced therapy and the results
are generally consistent with what we already know about inadequate response to advanced
therapy from the cohort studies or clinical trials in IBD.
assistant